» Articles » PMID: 36826154

A Novel Fatty Acid Metabolism-Associated Risk Model for Prognosis Prediction in Acute Myeloid Leukaemia

Overview
Journal Curr Oncol
Publisher MDPI
Specialty Oncology
Date 2023 Feb 24
PMID 36826154
Authors
Affiliations
Soon will be listed here.
Abstract

Acute myeloid leukaemia (AML) is the most common acute leukaemia in adults, with an unfavourable outcome and a high rate of recurrence due to its heterogeneity. Dysregulation of fatty acid metabolism plays a crucial role in the development of several tumours. However, the value of fatty acid metabolism (FAM) in the progression of AML remains unclear. In this study, we obtained RNA sequencing and corresponding clinicopathological information from the TCGA and GEO databases. Univariate Cox regression analysis and subsequent LASSO Cox regression analysis were utilized to identify prognostic FAM-related genes and develop a potential prognostic risk model. Kaplan-Meier analysis was used for prognostic significances. We also performed ROC curve to illustrate that the risk model in prognostic prediction has good performance. Moreover, significant differences in immune infiltration landscape were found between high-risk and low-risk groups using ESTIMATE and CIBERSOT algorithms. In the end, differential expressed genes (DEGs) were analyzed by gene set enrichment analysis (GSEA) to preliminarily explore the possible signaling pathways related to the prognosis of FAM and AML. The results of our study may provide potential prognostic biomarkers and therapeutic targets for AML patients, which is conducive to individualized precision therapy.

Citing Articles

Development of a propionate metabolism-related gene-based molecular subtypes and scoring system for predicting prognosis in bladder cancer.

Zheng F, Wang Z, Li S, Xiong S, Yuan Y, Zeng J Eur J Med Res. 2024; 29(1):393.

PMID: 39075554 PMC: 11285334. DOI: 10.1186/s40001-024-01982-6.


is Key to a Prognostic Multigene Signature and a Potential Therapeutic Target in Acute Myeloid Leukemia.

Zhong J, Huang K, Xie S, Tan A, Peng J, Nie D J Cancer. 2024; 15(9):2538-2548.

PMID: 38577610 PMC: 10988303. DOI: 10.7150/jca.90822.

References
1.
H Elsayed A, Rafiee R, Cao X, Raimondi S, Downing J, Ribeiro R . A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia. Leukemia. 2019; 34(3):735-745. PMC: 7135934. DOI: 10.1038/s41375-019-0604-8. View

2.
Nepstad I, Hatfield K, Gronningsaeter I, Reikvam H . The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells. Int J Mol Sci. 2020; 21(8). PMC: 7215987. DOI: 10.3390/ijms21082907. View

3.
Espinoza-Sanchez N, Gotte M . Role of cell surface proteoglycans in cancer immunotherapy. Semin Cancer Biol. 2019; 62:48-67. DOI: 10.1016/j.semcancer.2019.07.012. View

4.
Tallman M, Wang E, Altman J, Appelbaum F, Bhatt V, Bixby D . Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019; 17(6):721-749. DOI: 10.6004/jnccn.2019.0028. View

5.
Zhang W, Wang X, Zhang L, Geng D, Wang Y, Sun D . Inhibition of PLA2G4A Reduces the Expression of Lung Cancer-Related Cytokines. DNA Cell Biol. 2018; . DOI: 10.1089/dna.2018.4286. View